Rchr
J-GLOBAL ID：201801007267873880
Update date: Jun. 20, 2024
Takashi Fujimoto
Takashi Fujimoto
Affiliation and department：
Research field (1)：
Neurosurgery
Research theme for competitive and other funds (4)：
- 2020 - 2026 Drug development of central nervous system diseases using dynamic three-dimensional in vitro blood-brain barrier model
- 2021 - 2024 Development of a Perfusion-Based 3D Blood-Brain Barrier Model for Analysis of Cancer Brain Metastasis and Pharmacokinetics
- 2018 - 2023 血液脳関門保護をターゲットとした中枢神経疾患治療薬の開発
- 2017 - 2022 Three dimensional blood-brain barrier model
Papers (31)：
-
Takashi Fujimoto, Lindsey Williams, Daniel Quaranta, Riley Weaver, William Banks, Michelle Erickson. Regulation of CCL2 transport across the blood-brain barrier. Brain, Behavior, and Immunity. 2023. 114. 62-62
-
Lindsey M. Williams, Takashi Fujimoto, Riley R. Weaver, May J. Reed, Michelle A. Erickson. Heparan sulfate-dependent transport of CCL2 across an in vitro model of the human blood-brain barrier. 2023
-
Takashi Fujimoto, Michelle A. Erickson, William A. Banks. Neurotropism and blood-brain barrier involvement in COVID-19. Frontiers in Drug Delivery. 2022. 2
-
Daniel V. Quaranta, Riley R. Weaver, Kristen K. Baumann, Takashi Fujimoto, Lindsey M. Williams, Hyung Chan Kim, Aric F. Logsdon, Mohamed Omer, May J. Reed, William A. Banks, et al. Transport of the Proinflammatory Chemokines C-C Motif Chemokine Ligand 2 (MCP-1) and C-C Motif Chemokine Ligand 5 (RANTES) across the Intact Mouse Blood-Brain Barrier Is Inhibited by Heparin and Eprodisate and Increased with Systemic Inflammation. Journal of Pharmacology and Experimental Therapeutics. 2022. 384. 1. 205-223
-
Kei Sato, Shinsuke Nakagawa, Yoichi Morofuji, Yuki Matsunaga, Takashi Fujimoto, Daisuke Watanabe, Tsuyoshi Izumo, Masami Niwa, Fruzsina R Walter, Judit P Vigh, et al. Effects of fasudil on blood-brain barrier integrity. Fluids and barriers of the CNS. 2022. 19. 1. 43-43
ｍore...
MISC (1)：
-
諸藤陽一, 中川慎介, 藤本隆史, 佐藤慧, 松永裕希, 堀江信貴, 出雲剛, 松尾孝之. 急性期脳梗塞治療としてのファスジル動注療法の可能性. 脳血管内治療(Web). 2020. 5. Supplement
Return to Previous Page
